CMS Denial Of Visudyne Coverage Would Give Physicians No Option – Society
This article was originally published in The Gray Sheet
Executive Summary
A CMS denial of coverage for Visudyne (verteporfin) therapy for certain age-related blindness patients would have the effect of forcing physicians to conduct unethical trials, The Vitreous Society maintains in recent comments to the agency
You may also be interested in...
QLT/Novartis Visudyne Occult Data Expected 2004; Medicare Coverage Denied
QLT expects to have data on Visudyne in age-related macular degeneration patients with occult lesions from an ongoing Canadian and European trial by 2004
QLT/Novartis Visudyne Occult Data Expected 2004; Medicare Coverage Denied
QLT expects to have data on Visudyne in age-related macular degeneration patients with occult lesions from an ongoing Canadian and European trial by 2004
Visudyne Provides Test-Case For Medicare Coverage Of Off-Label Indications
The Centers for Medicare & Medicaid Services plans to ask investigators for unpublished information from a peer-reviewed study of QLT PhotoTherapeutic's Visudyne (verteporfin) before moving forward with its decision to expand coverage to off-label indications for age-related macular degeneration (AMD)